Azenta (AZTA) DIvidends Date & History

Key Takeaways

• Azenta, Inc. (AZTA) does not currently pay a dividend, with the last quarterly payment of $0.10 per share in December 2021.
• Current dividend yield is 0%, and payout ratio is N/A due to no ongoing dividends.
• The company prioritizes growth investments, strategic M&A, and share repurchases over dividends, with a $250 million buyback program authorized in December 2025.
• Strong balance sheet features $565 million in cash and marketable securities as of March 2026, low debt of $54 million, and positive free cash flow.
• No dividend growth streak; focus on capital allocation for long-term shareholder value without income distributions.
• Dividend initiation remains uncertain, hinging on sustained profitability and strategic shifts in a competitive life sciences sector.

Dividend Overview

Azenta, Inc. (AZTA), a provider of life sciences solutions including sample management and genomic services, does not pay a dividend currently. The company's most recent dividend was a quarterly payout of $0.10 per share, with an ex-dividend date of December 2, 2021, and payment on December 23, 2021. Prior to that, as Brooks Automation, it maintained quarterly dividends, but payments ceased following the 2021 rebranding and strategic pivot toward growth investments. With a current yield of 0% and no forward dividend rate, AZTA is neither a dividend growth stock nor a high-yield play. Instead, it appeals to investors seeking capital appreciation in the life sciences tools sector, where reinvested earnings support R&D, acquisitions, and share repurchases rather than distributions.

Dividend History and Growth

Azenta's dividend history reflects a modest profile that ended abruptly. Under its former name, Brooks Automation, the company paid quarterly dividends consistently through 2021, with payments of $0.10 per share in each of the four quarters that year, totaling $0.40 annually. Earlier years saw similar payouts, such as $0.40 in 2020 and higher amounts like $0.95 in 2019, though with varying payout ratios (e.g., 307% in 2019 indicating potential unsustainability). There were no increases or cuts announced leading up to suspension; the final payment aligned with the corporate name change and sale of its semiconductor business in late 2021. Since then, no dividends have been declared, and the long-term strategy emphasizes organic growth, M&A, and buybacks over resuming payments. No dividend growth streak exists post-suspension.

Dividend Sustainability and Payout Ratio

Without dividends, sustainability metrics like payout ratio are not applicable (listed as 0% or N/A across sources). Azenta maintains robust financial health supporting potential future payouts: trailing twelve-month operating cash flow of $63 million, levered free cash flow of $108 million, and $565 million in cash equivalents/marketable securities as of Q2 fiscal 2026 (ended March 31, 2026). Total debt stands at $54 million (debt-to-equity ratio of 3.18%), with a current ratio of 2.92 indicating strong liquidity. Earnings coverage is solid absent dividends, though recent quarters showed non-GAAP losses (e.g., -$0.04 EPS in Q2 2026). Low leverage and positive cash generation provide flexibility, but ongoing investments in productivity, R&D, and acquisitions (e.g., UK Biocentre) prioritize growth over distributions. Recent impairments highlight execution risks, but no debt pressure threatens stability.

Dividend Compared to Industry Peers

In the life sciences tools and medical instruments sector (previously tied to semiconductor equipment), Azenta's 0% yield trails peers. Comparable firms like TER (Teradyne, 0.15% yield), KLAC (KLA, 0.44%), AMAT (Applied Materials, 0.52%), and LRCX (Lam Research, 0.38%) offer modest dividends with payout ratios under 25%, backed by strong cash flows. Semiconductor equipment averages ~0.3-0.5% yields, emphasizing growth over high income. Azenta's profile aligns with non-dividend payers in high-growth biotech tools, where reinvestment trumps payouts, making it less competitive for yield-focused investors but suitable for total return seekers via buybacks.

AI Screener

Tickeron’s AI Screener is an AI-powered stock and ETF discovery tool that helps traders and investors filter the market based on technical patterns, fundamentals, trends, volatility, and AI-driven signals. Users can scan thousands of stocks and ETFs using customizable filters such as industry, market capitalization, technical indicators, price patterns, and performance metrics. It efficiently identifies dividend stocks, income-focused investments, trending stocks, breakout candidates, and market opportunities more effectively than manual screening. Explore the AI Screener to streamline your research.

Is This Stock Attractive for Dividend Investors?

Azenta (AZTA) holds limited appeal for traditional dividend investors seeking current income, given its 0% yield and absence of payments since 2021. Income-focused or conservative investors prioritizing steady quarterly payouts may find better options among peers like KLAC or AMAT with reliable low-single-digit yields. However, growth-oriented dividend investors could view it positively if initiation occurs, supported by $565 million cash, minimal debt, and positive free cash flow trends. The $250 million share repurchase program (through 2028) offers an alternative return mechanism, enhancing earnings per share and potentially supporting future dividends amid life sciences demand. Long-term investors tolerant of volatility in sample management and genomics may appreciate capital allocation discipline—favoring R&D and M&A—but recent execution shortfalls (e.g., Q2 2026 revenue miss) warrant caution. Overall, suitability hinges on tolerance for zero yield in exchange for growth potential, not immediate income.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer. Disclaimers and Limitations